Metoclopramide hydrochloride
Metoclopramide hameln is an antiemetic medicine. It contains the active substance called
"metoclopramide". The medicine works on the part of the brain that prevents nausea and vomiting.
Adults
Metoclopramide hameln is used in adults for:
Children and adolescents
Metoclopramide hameln is indicated for use in children (aged 1-18 years) only if other
treatment methods have proven ineffective or cannot be used for:
Metoclopramide hameln must not be used in children under 1 year of age (see "Children and adolescents" below).
Before starting treatment with Metoclopramide hameln, the patient should discuss with their doctor,
pharmacist, or nurse:
The doctor may order a blood test to check the level of blood pigment. If the levels are abnormal (methemoglobinemia), treatment with this medicine should be stopped immediately.
Treatment should not be continued for more than 3 months due to the risk of involuntary muscle contractions.
Uncontrolled movements (extrapyramidal symptoms) may occur in children and adolescents.
This medicine must not be used in children under 1 year of age due to the increased risk of
uncontrolled movements (see above: "When not to use Metoclopramide hameln")
The patient should tell their doctor, pharmacist, or nurse about all medicines they are currently taking or
have recently taken, as well as any medicines they plan to take. This is important because some
medicines may affect the action of Metoclopramide hameln or Metoclopramide hameln may affect the
action of other medicines.
In particular, the patient should inform their doctor if they are taking any of the following medicines:
During treatment with metoclopramide, the patient should not drink alcohol, as it enhances the
sedative effect of Metoclopramide hameln.
Pregnancy
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child,
they should consult their doctor or pharmacist before using this medicine.
If necessary, Metoclopramide hameln may be used during pregnancy. The doctor will decide on the
necessity of using the medicine.
Breastfeeding
It is not recommended to use Metoclopramide hameln during breastfeeding, as metoclopramide passes
into breast milk and may affect the baby.
The patient may feel drowsy, dizzy, or experience uncontrolled movements or may make sudden or
jerky movements and may have unusual muscle tension causing distortion of body position after
taking Metoclopramide hameln. This may cause impaired vision and ability to drive vehicles and
operate machines.
This medicine contains less than 1 mmol (23 mg) of sodium per ampoule (2 ml), i.e., the medicine is
considered "sodium-free".
The medicine is usually administered by a doctor or nurse. It should be administered as a slow
intravenous injection (over at least 3 minutes) or intramuscular injection.
Treatment of nausea and vomiting, including nausea and vomiting associated with migraine, and
prevention of nausea and vomiting associated with radiotherapy:
the recommended single dose is 10 mg. The dose can be repeated up to 3 times a day.
The maximum recommended daily dose is 30 mg or 0.5 mg/kg body weight.
Prevention of nausea and vomiting after surgical procedures: the recommended single dose is 10 mg.
Use in children and adolescents (aged 1 to 18 years)(in all indications)
The recommended dose is 0.1 to 0.15 mg/kg body weight, repeated up to 3 times a day,
administered as a slow intravenous injection.
The maximum daily dose is 0.5 mg/kg body weight.
Dosing table
Treatment should not be longer than 48 hours in the case of nausea and vomiting after surgical
procedures.
Treatment should not be longer than 5 days in the case of prevention of delayed nausea and vomiting
that may occur after chemotherapy.
Metoclopramide must not be used in children under 1 year of age (see section 2).
The dose may need to be reduced depending on kidney and liver function and overall health.
Age | Body weight | Dose | Frequency |
1-3 years | 10-14 kg | 1 mg | Up to 3 times a day |
3-5 years | 15-19 kg | 2 mg | Up to 3 times a day |
5-9 years | 20-29 kg | 2.5 mg | Up to 3 times a day |
9-18 years | 30-60 kg | 5 mg | Up to 3 times a day |
15-18 years | Over 60 kg | 10 mg | Up to 3 times a day |
The patient should inform their doctor about kidney problems. In patients with moderate or severe
kidney disorders, the dose should be reduced.
The patient should inform their doctor about liver problems. In patients with severe liver disorders,
the dose should be reduced.
The patient should immediately contact their doctor or pharmacist. The patient may experience
uncontrolled movements (extrapyramidal symptoms), drowsiness, decreased level of consciousness,
disorientation, hallucinations, and cardiovascular and respiratory disorders (cardiac arrest and
respiratory arrest).
If necessary, the doctor will order appropriate symptomatic treatment.
The patient should not take a double dose to make up for a missed dose.
In case of any doubts about using this medicine, the patient should contact their doctor, pharmacist, or
nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
If any of the following side effects occur, the patient should stop using this medicine immediately and
inform their doctor, pharmacist, or nurse:
Very common side effects(occurring in more than 1 in 10 patients) include:
Common side effects(occurring in less than 1 in 10 patients) include:
Uncommon side effects(occurring in less than 1 in 100 patients) include:
Rare side effects(occurring in less than 1 in 1000 patients)
Side effects with unknown frequency(frequency cannot be estimated from available data):
If the patient experiences any side effects, including any side effects not listed in this leaflet, they
should inform their doctor, pharmacist, or nurse. Side effects can be reported directly to the
Department of Monitoring of Adverse Reactions to Medicinal Products, Office for Registration of
Medicinal Products, Medical Devices, and Biocidal Products,
Al. Jerozolimskie 181C, 02-222 Warsaw,
Phone: 22 49 21 301,
Fax: 22 49 21 309,
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help to gather more information on the safety of this medicine.
The medicine should be stored out of sight and reach of children.
Do not use this medicine after the expiry date stated on the label or carton after EXP. The expiry
date refers to the last day of the month.
Medicines should not be disposed of via wastewater or household waste. The patient should ask
their pharmacist how to dispose of medicines that are no longer needed. This will help protect the
environment.
Metoclopramide hameln is a clear, colorless solution, free from visible particles, supplied in 2 ml
ampoules made of neutral glass type I.
Each pack contains 10 ampoules.
hameln pharma gmbh, Inselstraße 1, 31787 Hameln, Germany
Siegfried Hameln GmbH, Langes Feld 13, 31789 Hameln, Germany
hameln rds s.r.o., Horná 36, 900 01 Modra, Slovakia
Zakłady Farmaceutyczne POLPHARMA S.A., ul. Pelplińska 19, 83-200 Starogard Gdański, Poland
Date of last revision of the leaflet:2024-08-25
--------------------------------------------------------------------------------------------------------------------
The solution should be administered intravenously or intramuscularly.
Intravenous administration should be as a slow bolus (lasting at least 3 minutes).
Bulgaria | Metoclopramide hameln 5 mg /ml, solution for injection Метоклопрамид хамелн 5 mg/ml инжекционен разтвор |
Czech Republic | Metoclopramide hameln |
Croatia | Metoklopramid-klorid hameln 5 mg/ml, otopina za injekciju |
Hungary | Metoklopramid hameln 5 mg/ml oldatos injekció |
Poland | Metoclopramide hameln |
Romania | Metoclopramid hameln 5 mg/ml soluţie injectabilă |
Slovakia | Metoclopramide hameln 5 mg/ml injekčný roztok |
Slovenia | Metoklopramid hameln 5 mg/ml raztopina za injiciranje |
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.